MAJI (Exousia Pro) Net Margin %: 0.00% (As of Jan. 2021)


What is Exousia Pro Net Margin %?

Exousia Pro MAJI +5.90% Net Margin % is 0.00% as of Jan. 2021.

Net margin is calculated as Net Income divided by its Revenue. Exousia Pro's Net Income for the three months ended in Jan. 2021 was $-0.13 Mil. Exousia Pro's Revenue for the three months ended in Jan. 2021 was $0.00 Mil. Therefore, Exousia Pro's net margin for the quarter that ended in Jan. 2021 was 0.00%.

The historical rank and industry rank for Exousia Pro's Net Margin % or its related term are showing as below:


MAJI's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.815
* Ranked among companies with meaningful Net Margin % only.

Exousia Pro  (OTCPK:MAJI) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Exousia Pro Net Margin % Related Terms

Exousia Pro Net Margin % Historical Data

* Premium members only.

The historical data trend for Exousia Pro's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exousia Pro Net Margin % Chart

Exousia Pro Annual Data
Trend Apr11 Apr12 Apr18 Apr19
Net Margin %
0.00 0.00 0.00 0.00

Exousia Pro Quarterly Data
Oct11 Jan12 Apr12 Jul12 Oct12 Jan13 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MAJI vs HCCH, GRNV, AGBA: Net Margin % Comparison

For the Biotechnology subindustry, Exousia Pro's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exousia Pro Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exousia Pro's Net Margin % distribution charts can be found below:

* The bar in red indicates where Exousia Pro's Net Margin % falls into.


Exousia Pro Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Exousia Pro's Net Margin for the fiscal year that ended in Apr. 2019 is calculated as

Net Margin=Net Income (A: Apr. 2019 )/Revenue (A: Apr. 2019 )
=-0.125/0
= %

Exousia Pro's Net Margin for the quarter that ended in Jan. 2021 is calculated as

Net Margin=Net Income (Q: Jan. 2021 )/Revenue (Q: Jan. 2021 )
=-0.134/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Exousia Pro (MAJI) has a Net Margin % of 0.00% as of Jan. 2021. Net margin is the ratio of total net income to net sales. View historical data on Exousia Pro and its competitors.
Is Exousia Pro's Net Margin % too high?
Exousia Pro's current Net Margin % is 0.00%.
How does Exousia Pro's Net Margin % compare to HCCH and GRNV?
Exousia Pro's Net Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Exousia Pro and its competitors. Exousia Pro's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exousia Pro stock overvalued right now?
Exousia Pro (MAJI) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Exousia Pro (MAJI), the current Net Margin % is 0.00% as of Jan. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Exousia Pro Business Description

Address 7901 4th Street North, No. 23494, St. Petersburg, FL, USA, 33702
Exousia Pro Inc is a exosome-based biotechnology, develops and manufactures mammalian and plant-based exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company is developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field of oncology. The platform technology of the company also helps treating a broad spectrum of viral infections.